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Clinical validation and diagnostic rate/outcomes of a dual molecular diagnostic assay for
myotonic dystrophy 1
Maxime Cadieux-Dion, Isabelle Thiffault, Midhat Farooqi, Carol Saunders, Joseph Alaimo
Children’s Mercy Kansas City, Kansas City, Mo
Background

Results: Validation summary

Myotonic dystrophy type 1 (DM1) is caused by a (CTG)n repeat expansion in
the 3’ UTR of DMPK and is an important and often overlooked consideration in
the work up of a hypotonic infant. (CTG)n repeats are refractory to detection by
short read sequencing and therefore, require other specialized methods for
accurate quantification including PCR and Southern blot (SB) analysis. Current
laboratory-developed PCR tests are limited to amplification of >100 repeats
and require multiple reactions for either expansion detection or accurate sizing
due to amplification dropouts. Furthermore, SB is labor-intensive, expensive,
and has a significantly increased turnaround time. Here, we describe the
clinical validation and implementation of a new commercially available PCR
assay that overcomes these significant hurdles (AmplideX PCR/CE DMPK,
Asuragen).

A validation set of 23 samples was tested. Samples were selected to provide
multiple representatives in each numerical category throughout the dynamic
range which included the normal (5-34 repeats), premutation (35-49 repeats),
and various disease ranges (>50 repeats). We observed 100% concordance
between our results for this sample set and previously reported results with
100% sensitivity, specificity, accuracy, and precision. In addition, we were able
to clearly resolve zygosity in all samples. Mosaicism of at least 10% was
detectable.
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Figure 1: Method workflow. Samples undergo TP PCR and resolved using
capillary electrophoresis. A maximum of 200 repeats can be detected and
zygosity can be resolved using this method. In addition, detection of mosaicism
can be clearly identified. However, samples with greater than 200 repeats can
be resolved by gene specific PCR and agarose gel electrophoresis.

Results: Additional testing

Sample

n

Percent

Positive

8

28.6 %

Negative

20

71.4 %

11, 594-928
11, 920
11, ~500
13, ~660

Congenital hypotonia
Congenital hypotonia
Developmental delay
ID and muscular dystrophy

11, 600-900

19

Hypotonia, craniofacial abnormalities

0.75

Hip dysplasia
Handgrip myotonia, bradycardia, poor
vision

Alleles

1
2
4
6
9

14
13, 230, ~ 150-280
Mother of
5, 18, 60, ~428-594
proband 4
Mother of
20, ~100-230
proband 1

28
38

10

15
13

4

6

Angelman syndrome
Chromosome analysis
Microarray
NGS Exome
Fragile X
NGS Panel
Prader Willi syndrome
Spinal Muscular Atrophy
Pallister Kilian syndrome

20

16

10
1

1

Congenital
Nemaline
Myopathy

Prader Willi
Syndrome

1

0

Age
(years)
0.5
3
1.3
15

Proband

1

4

2
Figure 2: Most patients (20/25 patients) underwent additional testing

Results: Clinical results
Table 1: Since implementing this
test clinically, 28 individuals have
been tested.

1

Presenting feature

"Trigger finger", IBS

Table 2: In 6/25 patients (24% of total), we detected expanded alleles between
500-900 repeats and reported a diagnosis of DM1. Two of three parents who
underwent carrier testing following the diagnosis of an affected child were
found to have somatic mosaicism. In both cases, the expansion was
maternally-inherited. Interestingly, all mothers tested for the repeat expansion
showed signs of DM1, but none were previously diagnosed with the disease.

Unknown

X-linked
myotubular
myopathy

Figure 3: Diagnosis in patients negative for the expansion

Conclusions
1. We validated and implemented a faster, accurate, and cost-effective
approach to diagnosis DM1 molecular. The workflow of the test is streamlined
and can be performed within 7 hours with a total hands-on time of 1 hour for
each workflow.
2. Our laboratory tested 25 patients with clinical features suggesting DM1; 6
were positive for an expanded allele. In addition, we identified mosaicism in two
parental samples. The high diagnostic rate of DM1 indicates a potentially large
number of undiagnosed patients.
3. Our results suggests that DM1 testing should be ordered early on in infant
with hypotonia, potentially even prior to NGS and CGH-array. As such, we offer
DM1 along with PWS and SMA as a Congenital Hypotonia panel.
4. Considering the high recurrence of DM1, establishing the diagnosis is
essential to provide appropriate genetic counseling to the family.

